Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Didn't the company state they were backing off some things to focus on the new things that would be more beneficial to the company now and later pick things back up. I am sure the "experts" on misinformation will have something really medical to say in response and I look forward to it!
Same here
Short sales meaning delay in timing from time of sale to shares available. Happens in every stock. When supply is low at a price range these numbers increase. Using them in any way is a very often a distraction technique. Facts are facts, these numbers do not represent short traders!
So basically if the company can't sway the vote they want at the end with their "B" shares they want to have time to force it on the investors one way or another. Track record is this is just a split without the investors benefiting in any way from it. Got make sure Leo is getting his $500k a year for at least a couple more years while they fleece the sheep! So disappointed with this company. Every bit of news is offered up for the lastest investment group to cash in, nothing for real investors.
Every bit of news is later found that some "investor" was given a bunch of shares for "cash" the rise in price gives them value of shares the news allows them to sell the shares into the market. More shares available reduce value of stock price. So the news basically gets washed out by some financial deal the company had with an "investment" group or company. The most current one the MFO has at least loose tired to Leo's son. So guess you have to decide without all the facts what is going on behind the scenes with our investment money.
Look at that amazing long term shareholder value! Leo has really taken care of the folks that have stood beside the company... Just kidding all his positive announcements have been in line with the interest of others. Giving these entities opportunity to dump shares and make money off of everyone else buying his crap! Right now the ones winning are there MFO whom are at least loosely tide to his son. Long term investors have only lost.
Lots of opportunities for the company, just need to capitalize on one. Getting that first deal/partnership will be huge and not just for the money, but for the validation of the company and drugs.
IPIX had drugs that pharmaceuticals want. They need further vetting based on the smaller trials. Although management thought they were doing a great thing but hurrying things up they have to come to terms with the fact they aren't get there $50 billion deal. I am not sure where the people is in closing a deal by my guess it has something to do with Leo's inexperience. My hope is he swallows his pride and let's someone do the negotiating or stops trying to get the $50 billion deal. It's important for share holders to see progress a deal/partnership is all that is left that can be done now. Anyone knows that. IPIX needs to be verified to the pharma works with a reputable partner! Good luck!
If you follow the facts and data shorts have all but cleared out. The trading groups still have enough shares to swing it back and forth and potentially use distort tactics to help them signal and move. It's how some make money. Too much risk vs reward at this price point with potential news that would push the price substantially and lock it from pulling back. All in my opinion of course.
Love the smell of fear! Wonder if we close above .30 today. Indefinite news coming how high is thier risk tolerance? Good luck!
That it's not a true statement. Albeit they could put it in the contract that certain monies are designed for specific reasons or strategies. Most up front payments are for use at the discretion of the company and its best interests. Depending on the size of the partner and what role they are taking they could possibly be funding the trial at a 100%. If not IPIX would include thier expected costs plus extras. But anything is possible I guess.
Good luck!
IMO this is a clear sign of what the majority think. Something is about to change and probably not for the worse. Alright you have the doom and gloom posts. There really isn't much of a cartel left trying to take the company out, maybe a few opportunist left trying to trade in and out for pennies. I'm confident in my investment or I wouldn't still be around!
I very much enjoy the difference in opinion on potential success and failure of the company. Reminds me that some folks are actually nervous about how close the partnership really is now. Did I invest enough should I invest more should I loosen my load... All kinds of different possibilities running through folks minds. I for one am excited for the fact there is very little time left before something has to happen! I'm substantially invested in IPIX. Good luck!
This just shows support that investors believe things are on the rise. Good indeed to see but when that first partnership is announced then the price will not just gain the value of the partnership deal, but should also validate the company and considerations for the rest of the assets will be acknowledge and included in final price valuation. Basically shaking off of the false information being said for years!
I really don't think IPIX management cares at all about any crew. They are going the path that is best for the company and that changes from time to time. It will catch people off guard because without insider information no one knows what's coming. We can speculate based on information released but then again sometimes the direction change for reasons beyond any we know. I'm hopeful that it will catch certain people off guard, but I don't think that that is the companies focus.
Price seems to be holding strong in the high .20s. Was hoping to grab a few more in the low .20s before any big announcements. I noticed in the last PR the wording seemed pretty clear that they are confident in the first agreement coming soon. IMO
I want to add my opinion, only thing is my opinion will hold much more weight because I don't have a motive, and they have factual information readily available to confirm the values.
#Prurisol- based on recent data, deals and press releases, good(not great) results will easily add $5 a share within a few months.
#B-OM - good mid phase II results could escalate to a phase 3/4 very easily. Even with no partner announcement that swing is easily worth $1-2.
Lawsuit - there has been a lot of positive releases since the attack when we were running at $4 / share. There is no reason, other than manipulation, $4 is not within reach once it is dropped.
#Brilacidin - Phase III no matter what anyone tries to say, if this news is not attacked and manipulate heavily, is huge and will draw a lot of attention from a lot of folks!
#Kevetrin - Once this hits the wire in journals and through media, which is in the very near future there will be significant interest in investing in $CTIX
With up-list easily obtainable levels in the near future bigger boys will belly up to the table. This will could easily be $10-$15 by June 2016.
I am not here trying to manipulate, there are facts to support almost everything I said and is readily available with simple searching. Start here cellceutix.com check their Facebook for relevant recent deals and news that support the strength of the direction of the company! #CTIX
Know What You Own!
Where was it stated that this was going to start up in March of 2016? I can't seem to find it.
Know What You Own
Seems that a Purisol success is not as welcome as many thought it would be a year ago. Purisol was always one of the indicators I was looking for to determine just how amazing Dr. M's knowledge of animal to human drug models work. I will tell you I was expecting to see more from the Purisol trial before the K trial. I am very impressed with the K trial so far. If Purisol works even close to the mice models and Briliacidin OM works as advertised I will put all of my money behind the good doctor on any of his future en-devours! It is amazing what this man has done and is doing. If he proves himself to be able to use animal models more accurately than most, which with his background and experience is very possible, he will be know for much more than just these few drugs!
Know what you own!
lol, The market? really? You think because 99% of the shares are locked up and investors are sitting on them that nobody trusts Leo? This is laughable at best! less than 1% of the shares bouncing back an fourth to try and manipulate shares out of tight hands(which isn't working) it's not the market distrust, that is called investor confidence and patience!
Good luck in your position!
Know What You Own!
Good try
Cellceutix worked with the FDA in developing the SPA and was very clear in that. Then this "generally recommend", so it appears again you are being selective and falsely opinionated.By the the simple math would say 90 days is end of May, but hey who wants facts right?
I am guessing t's are crossed and i's are dotted and a May start would not be unreasonable!
When there are no shares available the only way volume increases is if price increases and someone has been working very hard to keep it under 1.10. Perhaps some kind of technical thing to keep new investors away. When the stocks gets out of the hands of the manipulators it is going to be a beautiful reversal.
You say -
"You can't totally blame the shorts, a bad article"
You are correct you have to add the manipulators... then you can easily blame them for exactly where it sits.
You can try to spin it anyway you want, there is no way we would be here if it wasn't exactly for (in this order) manipulators, the article, the lawsuit, manipulators!
Wonder if that time is sped up with the QIDP?
A huge thank you SLC for all your research and contibutions, to the facts, on this board!
Know what you own!
84 days from last treated patient is approx. February 10th... Sure wouldn't want to be standing around looking in when the data is released with enough information for Leo to PR preliminary results....
Know what you own!
I was advise in private exchange also it cautioned me to the fact that several things I asked him about what has been posted was never said or his words where twisted he is also under the know that some have used the information (nothing that wasn't public already) that he clarified, to alert some and not all to timing to possibly assist in manipulating. Again nothing he ever shared was not already out there just the fact that some will write articles with more detail that gets seen by a small group in advance of the general public. Basically time to attack any potential good news before the mass is fully understanding of what was released by the company.
Those times have passed as is clear by actions of some.
Know what you own!
Boom... Cellceutix rockin' and rollin'
Let the games begin!
Company's real value has expanded exponentially! Hold on to your proxys this is about to get real interesting!
Know what you own and who you are playing with!
That's exactly how I'm seeing it. Sullivan has study Rosen's tactics and that is why he is asking to expedite and not allow Rosen to keep changing. By Sullivan saying they accept the ONLY law firm representing anyone in this case past the deadline is a block on the typical rosen delat tactic. I wonder what compensation Cellceutix is seeking should they win, they are seeking something! I don't think the court is going to slow anymore delays, not only the fact that Sullivan had already proven the case to be about 103% wrongful, but also he carries a much bigger hammer than rosen!
Cellceutix wants to put this behind them. They have something they want to announce, but seems they want (or need) this taken care of.
This case is pretty open shut... the cases that will open against rosen and his straw man George, really are going to be ugly!
All in my opinion of course
Know what you own!
Great day today! Can't wait until we get to hear some of the details to these events uncovered.
Know what you own
Great science great management!
To many folks trying to down play the amazing game of chess we have witnessed. Where so many small Bios have failed we have smart management one step ahead!If it wasn't for the spectacular grab of the poly heist and that extremely intelligent move to be funded away from share price, we would have crashed.... In a very short time you will see the amazing results of the positioning into a position of strength, and how well it payoffs!!!
Know what you own!
I hope everyone is buckled in!
Great science great management and there are no facts to prove other wise!
Negative opinions yes, false information yes, fake deadlines yes, unsupported false evidence yes ... making up of how BP works yes, unrealistic views/opinions yes!
It is almost time and the INVESTORS know!
Know what you own!
News out - "Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer"
BEVERLY, MA--(Marketwired - November 16, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reports that, based upon ongoing laboratory studies, the Company intends to use docetaxel for the combination therapy arm in the planned Phase 2 clinical trial to treat patients with platinum-resistance ovarian cancer. Cellceutix is designing the multi-arm study to evaluate Kevetrin as a monotherapy and as a component of combination therapy.
In planning the combination therapy arm of the study, several different chemotherapies were tested with Kevetrin. Nude mice were implanted with a human ovarian cancer tumor. After tumors were established, mice were treated with 200 mg/kg of Kevetrin in combination with docetaxel at 15 or 30 mg/kg. Interim findings showed that mice treated with Kevetrin in combination with 15 mg/kg docetaxel exhibited a significant reduction in tumor growth. Kevetrin in combination with 30 mg/kg docetaxel further reduced tumor burden.
Cellceutix finds it encouraging that 6 of 10 tumors in the group treated with the combination of Kevetrin and 30 mg/kg docetaxel have been reduced to the point that they are not measurable.
The experiment is still ongoing. The determination of the final docetaxel dose has not yet been determined, as the Company needs to take into consideration docetaxel toxicity. The final data from the research will be used to support the planned Phase 2 trial, which remains subject to Food and Drug Administration (FDA) guidance and authorization to initiate the trial.
Alerts:
Sign-up for Cellceutix email alerts is available at http://cellceutix.com/email-alerts/#sthash.CRfqSmmY.dpbs
Cellceutix clinical trials on Clinicaltrials.gov:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is in a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Regurgitating inacurate information doesn'tmake it accurate. We never qualified to uplist. Not all the pieces where ever together. When we had the price we needed audited financials. And right at the same time that you showed up and the mako attack then the rosen suit .... right before all the pieces where out together.
Stating false, way far out, drug completion dates and false timelines doesn't make them any more true than what had been reported on clinical trials for anticipated completion. A little DD and there are plenty of facts to know how close this company is to moving up.
The only thing keeping company value and SP so far apart is false information being spread and that fake lawsuit. That lawsuit will be cleared up soon, the other will be crushed by real investors that are coming in!
Thank goodness that Leo and company are geniuses and had the company set to succeed with out a need for a high sp to find us throw such an attack, and amazing science and drugs to keep moving!
Know what you own!
I thought you said you were basing your comments off 5 eye doctors in your family. You might want to talk to them again, give them all the facts and ask is it more often they would use B or something else in everything they do that requires antibiotics.
Some quick research shows that injecting through the cornea had become very common and effective. To me it sounds like B - ocular may be right on time!
Know what you own!
So if they can't reformulate to penetrate it will have a niche, like 100% of all surgeries, 100% of all situations that the corneal epitheleum is penetrated and 100% of the time that a doctor would rather inject a little B to get a result with less irritant. Also if the other drug used has a long life in the body, B may be a better option as an injection because of it's short time in the body and less implication with influence the use of other needed drugs. Just the other side of the spectrum is all I am saying.
Know what you own!
Yes, he will have to have actual loss. It was stated clearly, but many don't like facts to get in the way!
Know what you own!
I believe there has been a reason for that. Many have tried to claim Cellceutix for pumping up their SP price by issuing multiple PRs. I find it great that the CEO keeps investors updated and never thought of it as an attempt to inflate share price. I do believe we have been able to obtain the financing and the shelf based on the lack of share price pumping. If the company wanted to pump the share price up they could have hired a firm to do it. I believe the company is very confident that the science will speak for itself and therefore has not gone out trolling to push up SP. With that said, once this starts hitting the mainstream and the real investors and smart money start hearing the real information that has been kept so quite for so long, I think things are going to go crazy. All in my opinion of course!
Know what you own!
Among all the inaccurate things that are stated about Cellceutix the top 2 seem to be time line and credibility. Both can be squashed with good DD. As the company moves forward, especially in such a position of success, there will be many that try to mince every word that is written and or said.
Facts -
The company never gave any time line to up-list except one time in an interview saying the plan was for this year (2015) The rumblings that this has lead investors wrong is very inaccurate! As good as Cellceutix has been at keeping investors updated(I for one have appreciated), has also keep the wolves close by the door. Giving them the opportunity to smash down every bit of news that is released and turn it in to a non event, as seen in the false SA article. So they will keep carrying that torch and may proclaim that partner or up-list is the only way to save the company.The company doesn't require a high SP to conduct and continue through trials this has been discussed ad nausseam! They only thing the attacks on the company have done was drop SP it hasn't slowed anything else down! Well maybe partner discussions, but I don't even think that matters as Cellceutix stands in a position to negotiate anyway.
I would also like to state that Cellceutix has been working very hard to do the up-list so they are reporting and filing at the level required to be on NASDAQ, they aren't trying to con anybody.
When your doing your DD find it in print. You will be told things like Phase 2 is meaningless phase 3 is the answer, the same thing was said about phase 1 to phase 2. Phase 3 is a given now and just waiting for the "real" time it takes to set up a trial. But if you look at the phase 2 results you will see phase 3 has been very de-risked by the quality of the results. Kevetrin is the same thing phase one took longer than expected(welcome the world of medicine development). But the quality of the results are outstanding, by a hospital that is equally outstanding!
Cellceutix isn't a guaranteed success by no means. But if you take a look at where it is, I would much rather be putting my money in a bio with 5 trials, 3 major drugs and phase 2s going on and completed and a phase 3 about to start, over a bio with one drug. Do the math look around compare values of companies.
When you get to money "issue" they have a lot of funding on hand, should they need it. Take a good look at how much the company is burning through! They are using a lot of grants and some trials they are just supplying the drugs.
Remember it is the internet where names have been change to protect... everybody... so consider the source of the information you receive. Then make a real assessment of the company if you are really considering investing in the company on the long side!
Know What you own
IMPORTANT INFORMTION
re-posted from Slcimmuno
1) UPCOMING MILESTONES / CATALYSTS
SCIENCE
- Start of B-ABSSSI (Phase 3) (With Fast-Track designation, per QIDP)
- Completion of K (Phase 1) (more dets as to safety, efficacy)
- Initiation of several K phase 2, 2/3 trials (ovarian, pancreatic, AML) (more frequent dosing likely, grant support--addtl Orphan designation/s)
- Meeting w / FDA on K-pediatric retinoblastoma (rare disease)
- Phase 2 B-OM update
- Phase 2 P update/completion
- ABX platform -- progress on anti-fungals, anti-biofilm (MTA signed for B-prophylactic testing), gram-neg compounds; GI targets (Chrons, IBD, H Supportiva)
OPERATIONS
- Financing in place (shelf, Aspire)
- 1st Shareholder meeting (Dec 15... Be it pitchfork or rose petal in feel)
- NASDAQ uplisting (if $2 is maintained)
- Class Action Defense (Legal)
- Partners: still think this is likely farther off... Post Ph III ABSSSI for ABX... And will it be by indication or for whole platform? Kevetrin, the wildcard... As a case study, see CELG-Nurix deal (p53)
https://blogs.shu.edu/cancer/2015/09/30/ubiqu...d-celgene/
2) CURRENT TRIALS
Clinical Trials
Overall - https://clinicaltrials.gov/ct2/results?term=c...rch=Search
1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1
2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3
3. K (Phase 1, recruiting): https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=4
4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=5
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product
Company Website:
cellceutix.com